MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Pliant Therapeutics Inc

Chiusa

1.44 1.41

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.38

Massimo

1.51

Metriche Chiave

By Trading Economics

Entrata

-6.4M

-56M

Dipendenti

171

EBITDA

-10M

-59M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+463.38% upside

Dividendi

By Dow Jones

Utili prossimi

5 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-8.6M

89M

Apertura precedente

0.03

Chiusura precedente

1.44

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Pliant Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 lug 2025, 21:01 UTC

Utili

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

18 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

18 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Basic Materials Roundup: Market Talk

18 lug 2025, 20:46 UTC

Utili

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 lug 2025, 20:39 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 lug 2025, 20:36 UTC

Utili

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 lug 2025, 20:16 UTC

Acquisizioni, Fusioni, Takeovers

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 lug 2025, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

18 lug 2025, 20:02 UTC

Discorsi di Mercato

Gold Higher to Close Out Week -- Market Talk

18 lug 2025, 19:14 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 lug 2025, 19:06 UTC

Discorsi di Mercato

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 lug 2025, 18:24 UTC

Utili

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 lug 2025, 18:19 UTC

Utili

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 lug 2025, 18:11 UTC

Acquisizioni, Fusioni, Takeovers

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 lug 2025, 18:11 UTC

Utili

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 lug 2025, 17:35 UTC

Discorsi di Mercato

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 lug 2025, 16:29 UTC

Discorsi di Mercato

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 lug 2025, 16:28 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 lug 2025, 16:22 UTC

Utili

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Financial Services Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Energy & Utilities Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Basic Materials Roundup: Market Talk

18 lug 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

18 lug 2025, 16:04 UTC

Utili

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 lug 2025, 15:58 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

18 lug 2025, 15:58 UTC

Discorsi di Mercato

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 lug 2025, 15:47 UTC

Discorsi di Mercato
Utili

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Confronto tra pari

Modifica del prezzo

Pliant Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

463.38% in crescita

Previsioni per 12 mesi

Media 8 USD  463.38%

Alto 17 USD

Basso 3 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Pliant Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

6 ratings

1

Acquista

5

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.43 / 1.6Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Weak Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.